Gene Therapy
Developers of gene-replacement and gene-delivery therapeutics.
Leadership as of 2026-10-27: Lagging. Relative to SPY: 5 sessions −2.6pp, 21 sessions −16.6pp, 63 sessions −19.8pp. Participation 0%; 8 of 10 members eligible.
- 21-session excess -16.6pp
- 63-session excess -25.3pp (robust)
Economic family: Biotechnology
Member companies
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%